Into 2025: APAC’s Medtech Innovation And Investment Climate Emerging Into The Light

Technology Developers And Funders Encouraged By Ecosystem Trends

Medtech innovators in the APAC region have in recent years seen a slowdown in investment following a combination of rising costs, supply chain challenges and inflationary pressures. But there is light at the end of the tunnel, says MedTech Innovator APAC leader Fredrik Nyberg.

APAC
• Source: Shutterstock

By international comparisons, the Asia Pacific (APAC) region currently claims to have the fastest-growing medtech clusters.

The industries in Singapore, Japan, Korea and Australia often benefit from government subsidies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

More from New Science

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By 

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By 

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.